KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Four-year survival outcomes with dostarlimab plus chemotherapy in mismatch repair deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer in the RUBY trial.

Matthew A Powell, Henrik Roed, Lyndsay J Willmott, David Cibula, Destin Black, Giorgio Valabrega, Sudarshan Sharma, Stefan Kommoss, Lisa M Landrum, Ingrid Boere, Cara Mathews, Vladyslav Sukhin, Michael A Gold, Caroline Lundgren, Sarah E Gill, Lucy Gilbert, Ilana Cass, Mitchell I Edelson, Joseph Buscema, Nicole S Nevadunsky, Kari Ring, Bhavana Pothuri, Helen D Eshed, Carolyn McCourt, Robert L Coleman, Matthew Grimshaw, Laura Austin, Magdalena Zajac, Brian Slomovitz, Trine Nøttrup

Gynecol Oncol S0090-8258(26)01985-2

PMID42215378
PMCID-
DOI10.1016/j.ygyno.2026.05.008
发表日期2026-05-29
摘要

摘要

OBJECTIVE: Dostarlimab+carboplatin-paclitaxel (CP) demonstrated significant improvement in progression-free survival (PFS) and clinically meaningful improvement in overall survival (OS) vs CP alone among patients with dMMR/MSI-H primary advanced/recurrent endometrial cancer (EC) in Part 1 of the randomized phase 3 RUBY trial (NCT03981796). We report updated efficacy and safety data with approximately 4 years of follow-up. METHODS: Patients were randomized 1:1 to receive dostarlimab+CP or placebo+CP followed by dostarlimab or placebo up to 3 years or until disease progression. Descriptive analyses of OS and PFS were conducted in the dMMR/MSI-H population (median follow-up, 55.6 months). Post hoc conditional survival analyses and a mixture cure model (MCM) fitted to PFS data to estimate the proportion of patients who had curative potential are presented to provide prognostic insights into long-term survival. RESULTS: Dostarlimab+CP demonstrated sustained OS and PFS benefits. Median PFS and OS were not reached with a 66% reduction in risk of death vs placebo+CP. PFS curve plateauing (only 4 progression events with additional 2.5 years follow-up since the previous PFS analysis at interim analysis 1) demonstrated durable disease control. Patients alive at the 1- and 2-year landmarks had >80% probability of remaining alive an additional 3 and 2 years, respectively. At 4 years, the MCM analysis estimated a cure rate with dostarlimab of 54% (95% CI 35%-72%). No new safety signals were observed. CONCLUSIONS: At 4 years, RUBY demonstrated sustained remission and long-term survival benefit, suggesting the potential for curative intent with dostarlimab+CP in patients with dMMR/MSI-H primary advanced or recurrent EC.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。